Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Alteogen is consolidating two of its subsidiaries (Altos Biologics and Alteogen Healthcare) into one, receiving new shares issued by the surviving entity (Altos Biologics). This is an internal organizational restructuring involving no new cash outlay, with investment amounts combined solely for accounting purposes.
📊 [Key Disclosure Details & Financial Highlights]
- Target Corporation: Altos Biologics Corp. (Subsidiary of Alteogen)
- Main Business: R&D of Pharmaceuticals
- Number of Shares to Acquire: 1,059,695 shares (Acquisition of new shares)
- Acquisition Amount: KRW 39.88B (13.24% of total equity of KRW 301.13B)
- Total Shares and Ownership Ratio After Acquisition: 6,059,695 shares (62.89%)
- Purpose of Acquisition: Enhancing operational efficiency by integrating business organizations via merger between subsidiaries
- Scheduled Acquisition Date: 2025-05-23
- Board Resolution Date: 2025-04-03
- Transaction Structure & Valuation: The merger involves the surviving subsidiary (Altos Biologics Corp.) absorbing the merging subsidiary (Alteogen Healthcare Corp.). There is no additional cash capital injection from Alteogen. The acquisition value reflects the new shares allocated based on the merger valuation price of KRW 37,630 per share.
- Financial Summary of Target Corporation (Altos Biologics Corp., Unit: KRW Millions):
- Current Year: Total Assets 87,464 / Total Liabilities 10,530 / Total Equity 76,934 / Capital Stock 3,782 / Revenue – / Net Loss -4,561
- Previous Year: Total Assets 63,427 / Total Liabilities 5,562 / Total Equity 57,865 / Capital Stock 3,473 / Revenue – / Net Loss -3,339
- Year Before Previous: Total Assets 61,862 / Total Liabilities 4,239 / Total Equity 57,622 / Capital Stock 3,445 / Revenue – / Net Loss -2,713
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Completion of Subsidiary Merger and Reflected Ownership Status
This share acquisition is a procedure to receive newly issued shares resulting from a merger between two subsidiaries of Alteogen, involving no actual cash outflow. It is important to verify whether the subsidiary merger process is successfully finalized by the scheduled date of May 23, 2025, to determine if the planned corporate structure streamlining has been achieved as intended. The finalized progress and shareholding status can be verified in the ‘Status of Investments in Other Corporations’ and Notes to Financial Statements sections of upcoming quarterly, half-yearly, or annual business reports.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
